Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:50:31.317Z.
Calculation as of: 2026-10-06T21:50:31.317Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$110.30M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.14M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.94M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.09M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.98M
EV/EBIT Ratio
N/A
TTM Avg
56.93x
3Y Avg
94.02x
5Y Avg
53.96x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $110.30M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | N/A | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $107.17M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | N/A | 56.93x | 94.02x | 53.96x |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | N/A | N/A | N/A | N/A |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
